🔴 Senti Biosciences is trading 7.7% down today after asset divestiture and restructuring with Celadon Partners

Senti Biosciences is trading 7.7% down at $0.42 as investors react to a strategic transaction and restructuring agreement with Celadon Partners.

• The company is divesting the majority of its Gene-Circuit pipeline, including SENTI-202, to a Celadon-backed entity for up to $60 million in potential CVR milestones.
• Senti will retain only its early-stage Regulator Dial assets and is operating with just $6.5 million in cash, highlighting severe financial stress and a highly dilutive change-of-control financing structure.